The specific influence of individual splicing factors on the efficacy of chemotherapy drugs used in head and neck cancer has only been studied in the case of SRSF3, which was shown to be associated with reduced sensitivity of cancer cells to Paclitaxel (PTX) treatment [11]. This evidence concerns the gene SRSF3 and cancer.